Assessing Public Health Models in France: A Systematic Review

Author(s)

Moreau R1, Massetti M1, Ajjouri R2, Blachier M1, Le Lay K3, Leleu H4
1Public Health Expertise, Paris, 75, France, 2Roche, Boulogne-Billancourt, 92, France, 3Roche, Boulogne-Billancourt, Hauts-de-Seine, France, 4Public Health Expertise, Paris, IDF, France

OBJECTIVES: In France, models are commonly used for HTA and pricing negotiations. However, the Sars-CoV2 epidemic has sparked interest in predictions unrelated to efficiency, focusing on epidemiology, community health, health economics, environmental factors, and healthcare institutional assessment, specific to public health (PH).

Our objective was to evaluate the use of PH models (PHM) in assessing PH-related outcomes in France, including indication, methodology, developers, and decision-making implications.

METHODS: We conducted a systematic review of PHM in France, using PubMED/MEDLINE (since 2015) and ISPOR database. We also reviewed institutional websites, including French HTA, parliamentary, and national research organizations.

Keywords included different types of models (e.g., Markov model, discrete-event simulation [DES], microsimulation). RCT and CEM assessing drugs were excluded, while articles simulating PH initiatives in France were included.

RESULTS: 286 publications were identified, and 44 were retained after screening. Infectiology and vaccination models accounted for 30% of results, with a significant portion focusing on COVID-19 (14%). Cancer screening (14%), nutrition (11%), organizational measures and care pathways (9%) were also commonly studied.

Microsimulations and DES were frequently employed (31%), particularly for topics involving individual behavior and choices like COVID-19, oncology screening, and nutrition. Markov models were commonly used and applied across various subjects.

Only 3 PHMs were identified from French agencies, conducted by Santé publique France (SPF) and the French National Cancer Institute (INCa). Except for CEA, only 13 articles were identified on HAS website, none of which presented original models.

CONCLUSIONS: This review shows the increasing trend of PHM since the COVID-19 crisis, confirmed at ISPOR Europe 2022, with France presenting the most PHM studies. It reflects public authorities' support for evaluating health promotion and prevention programs, considering various aspects.

PHMs offer a comprehensive approach for manufacturers to assess and predict the value of health innovations, benefiting practitioners, authorities, and encouraging pharmaceutical companies' involvement in healthcare.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EPH165

Topic

Methodological & Statistical Research, Study Approaches

Topic Subcategory

Literature Review & Synthesis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×